tively at age 3, and 0X20 and 0-26 at 4 5 years. Altogether 260 (1.3%) of the total cohort were found to have heights --2SD
scores. The mean growth velocity of 2742 children measured at 3 and 4*5 years of age was similar to that of the national standards, 7*14 cm/year in boys and 7*21 cm/year in girls.
Foliow up data was available from 149 children whose heights were confirmed to be -2SD scores. Of these 69 were already under the care of paediatricians. Thus far diagnoses in the 149 have included growth hormone deficiency (n=2), Turner's syndrome (n=2), Noonan's syndrome (n= 4), and emotional deprivation (n= 1). Ways in which ascertainment and detection of treatable causes of short stature could be improved are discussed and it is concluded that community growth screening is a useful Growth screening has been used as a method of monitoring the general level of the health of a population,l but it can also be used to help identify individual children who may have undiagnosed conditions that affect their growth.5 Recent national recommendations relating to child health surveillance recommend that all children should be screened for height at 3 and 4-5 years of age. 6 Most previous height screening programmes in the UK have been established on a research basis using specialised personnel.5 7 The limitation of these studies is that they are expensive and without a firm population base. For screening to be established on a service basis it must be incorporated into the continuing child health surveillance programme. Growth paediatric endocrinologist and 13 are still under evaluation. Of the 69 who were already seeing a paediatrician, 21 were already seeing the paediatric endocrinologist. Twelve of these had pathological reasons for their short stature, three had had intrauterine growth retardation, and six had familial short stature.
The new pathology identified as a result of the screening was: one child with growth hormone insufficiency, two children with Noonan's syndrome, one child with emotional deprivation, one with pseudohypoparathyroidism, one with hypomelanosis of Ito, and one probable bony dysplasia.
Discussion
Growth screening may be an appropriate way of monitoring the health of the community and for the early identification of treatable causes of short stature. The Hall report recommended that all children should be routinely measured at 3 and 4-5 years,6 but if this recommendation is to be adopted, a simple cost effective method of screening the height of the total population of children has to be devised. We have attempted to achieve this goal by incorporating growth screening into the existing framework of the child health surveillance programme.
If we were to estimate the cost of carrying out the primary growth screening on a service basis then the cost of the screening programme can be broken down into a series of different elements. The first of these is health visiting times. If we assume that it takes three minutes per measurement (including recording time) then a total of 1000 hours of health visitor time has been used in the study so far. This equates to approximately £9000. The Minimetres used cost £19 each and were supplied to 130 health visitors at a cost of C2470. These costs leave out that of data entry. The study did involve a significant extra task for health visitors in the district not only because of the introduction of height measurements as a standard part of the developmental checks but also because the additional clerical tasks involved in filling in forms, and ensuring that the details were correct. The backlog of data entry on to the computer was simply due to lack of data entry personnel and it is predicted that when this moves from a 'research based' function to a 'service based' function it will no longer be a problem.
At present the majority of child health surveillance in this age group is carried out by either health visitors, clinical medical officers, or GPs. In our previous study we have shown that health visitors' measurements, although not ideal, are reasonably accurate for the assessment of short stature.9 With the provision of appropriate equipment, training, and a central reporting facility, growth screening can be accomplished by health visitors and community doctors as part of their checks on preschool children.
Despite having received training in using the Microtoises, some of the health visitors used either the Oxford wall chart or a tape measure.
This may have introduced greater inaccuracy. The wall chart was used in 9.6% of the 3 year olds and 4/3% of the 4-5 year olds (the accuracy of this device was discussed in our earlier paper9). The tape measure was used to measure 23% of the 3 year olds and 5% of the 4-5 year olds. The accuracy of this method has not been assessed, and with the advent of the Minimetre this is the recommended piece of equipment for routine screening of height in children.
Throughout the district about 900/o of health visitors have cooperated with the studies as have fundholding and non-fundholding GPs. Some health visitors reported practical difficulties in obtaining measurements particularly in 3 year olds. Further administrative problems have arisen due to late returns and a backlog of data entry suggesting areas for improvements in overall coverage. Overall, however, ascertainment in our preliminary studies has been between 70 and 80%.
The frequency distribution of height SD scores for the 20 338 children shows a shift to the right, especially at the younger ages. The sample size means it is unlikely that this change is due to chance. The shift in height SD scores reflects the secular trend in growth but it is greater than that described by To date only 2 1/% of the short stature identified by screening was attributable to organic disease. This compares with 17% in the Wessex studyl7 and 18% in the Newcastle upon Tyne study.5 Of the specific diagnoses causing short stature the most important are growth hormone deficiency, Turner's syndrome, thyroid deficiency, and emotional deprivation. In our study two children out of 20 000 screened were found to be growth hormone deficient, compared with a reported incidence of one per 3000-4000; two cases of Turner's syndrome were found compared with a reported incidence of one per 2500-3000. Thyroid deficiency is rarely found in this age group now that congenital cases are excluded. The incidence of emotional deprivation is unknown.
The reasons for the low incidence of growth hormone deficiency and Turner's syndrome is still to be determined. Only 750/0 of the population were screened and there may be undiscovered cases in those who were not screened. There may be further children with Turner's syndrome and growth hormone deficiency who are as yet undiagnosed among those children still being followed up in the community clinics. The more intriguing possibility is that some of the children with these conditions may still be within the normal height centiles yet they are growing slowly. Examination of growth charts specific for Turner's syndrome18 indicates that 40 to 50%/o of such girls are above the third centile at 3 and 4-5 years. This may also be true for a smaller proportion of growth hormone deficient children who were of normal size at birth. If we are to detect these children at 3 and 4-5 years screening must also encompass an estimate of growth velocity. Our height velocity data are similar to those reported by Tanner and Whitehouse in 1966 and are in contrast to reports from Southampton that height velocity has increased.7 This requires clarification as measurement errors are unlikely to explain the discrepancy in the mean velocity and mean velocity SD scores when the sample size is so large. The SD of the velocity SD score, however, was larger than expected and included 'blips' at each end of the distribution that can be attributed to measurement error. As we have argued before, health visitor measurements may not be suitable for velocity assessment.9 Sorva et al have devised standards using changes in height SD scores as indirect measurements of growth velocity,19 but these require further study.
In conclusion, with all its limitations we have described a model for a relatively cheap and realistic programme of height screening and follow up of short children. The advantages of such a programme are that it keeps the majority of children who are short for nonpathological reasons away from expensive hospital facilities.
